Written by Babatunde Carew
Spoon Feed
Pimavanserin/atomoxetine combination significantly reduced OSA severity and was well tolerated compared to placebo.
Ato-pima – the dream team?
Untreated obstructive sleep apnea (OSA) increases the risk of cardiovascular disease, causes excessive daytime sleepiness, and reduces quality of life. Treatment with continuous positive airway pressure (CPAP) remains the gold standard, and to this point, no pharmacologic therapy for OSA has demonstrated proven benefits as a primary treatment option.
This double-blind, randomized, crossover trial assessed whether a 1 week course of pimavanserin (an atypical antipsychotic) plus atomoxetine (Ato-Pima) reduces OSA severity by enhancing pharyngeal muscle tone and reducing respiratory-related sleep disturbances. Among 18 adults with moderate-to-severe OSA, Ato-Pima reduced the apnea-hypopnea index (AHI) by 42% (−16.9 events/hr; P<0.001), improved nadir SpO₂ (+5%), and decreased arousal index (−10.8/hr) compared to placebo. No serious adverse effects or QTc prolongation occurred, though a mild increase in heart rate was noted. Limitations include small sample size, short study duration, and exclusion of patients with major organ system disease.
How does this change my practice?
This study does not change my current practice. Bigger trials are needed to evaluate the long-term efficacy and safety of this medication combo compared to CPAP therapy. We also need data on the proportion of patients who achieve an AHI <5 events/hour – the threshold for successful OSA treatment per the AASM. That said, the findings are encouraging and suggest that pharmacologic options may eventually become viable, particularly for patients who decline or fail standard therapies.
Source
The Combination of Pimavanserin and Atomoxetine Reduces OSA Severity: A Randomized Crossover Trial. Chest. 2025 Mar 28:S0012-3692(25)00404-0. doi: 10.1016/j.chest.2025.03.013. Epub ahead of print. PMID: 40158847
